Actinium Pharmaceuticals, Inc. (ATNM) | Investment Case

1. Company Snapshot

1.a. Company Description

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies.Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities.

It has collaboration with Astellas Pharma, Inc.to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors.The company was incorporated in 2000 and is based in New York, New York.

Show Full description

1.b. Last Insights on ATNM

The recent 3 months performance of Actinium Pharmaceuticals, Inc. was negatively impacted by a series of class action lawsuits and securities fraud investigations. The lawsuits, filed by various law firms, alleged that the company made false and misleading statements about its business and financial performance. The investigations, led by firms such as Glancy Prongay & Murray LLP and Law Offices of Howard G. Smith, also focused on potential securities law violations.

1.c. Company Highlights

Last Price	1.43
Change Percentage	-1.38%
Open	1.43
Previous Close	1.45
Market Cap ( Millions)	45
Volume	82735
Year High	2.41
Year Low	1.03
M A 50	1.45
M A 200	1.5

FCF Yield	-56.14%
Dividend Yield	0.00%
ROE	-151.67%
Debt / Equity	8.29%
Net Debt / EBIDTA	147.59%
Price To Book	3.24
Price Earnings Ratio	-1.29
Price To FCF	-1.78
Price To sales	49.57
EV / EBITDA	0.22

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Dec -01

Source: prnewswire.com

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Nov -17

Source: newsfilecorp.com

Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

Nov -04

Source: prnewswire.com

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct -27

Source: prnewswire.com

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct -24

Source: prnewswire.com

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct -13

Source: prnewswire.com

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct -13

Source: prnewswire.com

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

Sep -02

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Radiotherapies

Expected Growth: 15.4%

Growing demand for targeted cancer therapies, increasing adoption of alpha-therapy, and Actinium-225's potential to selectively kill cancer cells while minimizing harm to healthy cells drive the market growth.

7. Detailed Products

Iomab-B

A CD45-targeting radioimmunotherapy for the treatment of relapsed or refractory acute myeloid leukemia (AML)

Actimab-A

A CD33-targeting radioimmunotherapy for the treatment of newly diagnosed AML

Actimab-M

A melanoma-targeting radioimmunotherapy for the treatment of metastatic melanoma

8. Actinium Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Actinium Pharmaceuticals, Inc. is medium due to the presence of alternative cancer treatments, but the company's focus on targeted alpha therapy provides a unique value proposition.

Bargaining Power Of Customers

The bargaining power of customers is low for Actinium Pharmaceuticals, Inc. as the company's products are primarily used in hospitals and clinics, and patients have limited negotiating power.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium for Actinium Pharmaceuticals, Inc. as the company relies on a few key suppliers for raw materials, but has some flexibility to negotiate prices.

Threat Of New Entrants

The threat of new entrants is high for Actinium Pharmaceuticals, Inc. due to the growing interest in targeted alpha therapy and the potential for new companies to enter the market.

Intensity Of Rivalry

The intensity of rivalry is high for Actinium Pharmaceuticals, Inc. due to the competitive landscape of the pharmaceutical industry and the presence of established players.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	5.49%
Debt Cost	3.95%
Equity Weight	94.51%
Equity Cost	4.38%
WACC	4.36%
Leverage	5.81%

11. Quality Control: Actinium Pharmaceuticals, Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Xeris Biopharma

A-Score: 5.2/10

Value: 6.2

Growth: 7.1

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 2.7

1-Year Total Return ->

MannKind

A-Score: 4.0/10

Value: 3.2

Growth: 8.7

Quality: 7.1

Yield: 0.0

Momentum: 2.0

Volatility: 3.0

1-Year Total Return ->

Kymera Therapeutics

A-Score: 3.8/10

Value: 6.4

Growth: 3.1

Quality: 4.9

Yield: 0.0

Momentum: 6.5

Volatility: 2.0

1-Year Total Return ->

Actinium Pharmaceuticals

A-Score: 3.7/10

Value: 6.8

Growth: 5.9

Quality: 3.1

Yield: 0.0

Momentum: 5.0

Volatility: 1.3

1-Year Total Return ->

Syros Pharmaceuticals

A-Score: 3.5/10

Value: 8.2

Growth: 5.6

Quality: 7.4

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

OmniAb

A-Score: 2.7/10

Value: 7.7

Growth: 1.6

Quality: 4.6

Yield: 0.0

Momentum: 0.0

Volatility: 2.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

11.31%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

4.36%

Actinium Pharmaceuticals, Inc. - US00507W2061

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ATNM

1.c. Company Highlights

Lower Quality

Stable Momentum

Fairly Valued

Earnings Beats

Medium Volatility

Strong Momentum

Weak Momentum

Earnings Miss

Average Quality

Cheaper

Average Growth

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Radiotherapies

Expected Growth: 15.4%

7. Detailed Products

Iomab-B

Actimab-A

Actimab-M

8. Actinium Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Actinium Pharmaceuticals, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.43$

Current Price

1.43$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA